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OBJECTIVE — To examine antidepressant use before and after the diagnosis of diabetes.
RESEARCH DESIGN AND METHODS — This study was a longitudinal analysis of
diabetic and nondiabetic groups selected from a prospective cohort study of 151,618 men and
women in Finland (the Finnish Public Sector Study, 1995–2005). We analyzed the use of
antidepressantsinthose493individualswhodevelopedtype2diabetesandtheir2,450matched
nondiabetic control subjects for each year during a period covering 4 years before and 4 years
after the diagnosis. For comparison, we undertook a corresponding analysis on 748 individuals
who developed cancer and their 3,730 matched control subjects.
RESULTS — In multilevel longitudinal models, the odds ratio for antidepressant use in those
who developed diabetes was 2.00 (95% CI 1.57–2.55) times greater than that in nondiabetic
subjects. The relative difference in antidepressant use between these groups was similar before
and after the diabetes diagnosis except for a temporary peak in antidepressant use at the year of
the diagnosis (OR 2.66 [95% CI 1.94–3.65]). In incident cancer case subjects, antidepressant
use substantially increased after the cancer diagnosis, demonstrating that our analysis was
sensitive for detecting long-term changes in antidepressant trajectories when they existed.
CONCLUSIONS — Awareness of the diagnosis of type 2 diabetes may temporarily increase
the risk of depressive symptoms. Further research is needed to determine whether more prev-
alentuseofantidepressantsnotedbeforethediagnosisofdiabetesrelatestoeffectsofdepression,
side effects of antidepressant use, or a common causal pathway for depression and diabetes.
Diabetes Care 33:1471–1476, 2010
D
iabetes is a chronic disease with
substantial public health impor-
tance, but its psychological effects
are not well understood (1–4). The di-
agnosis of diabetes in itself may be a life
event that increases risk of depressive
symptoms, arising from the awareness
of having a pernicious chronic condi-
tion (2). However, it is equally possible
that psychological impacts are not ap-
parent until patients reach an advanced
disease state because at diagnosis type 2
diabetesusuallyhasmildsymptoms(3).
The suggestion that depressive symp-
toms among nondiabetic individuals also
increase the risk of diabetes complicates
the examination of the effect of diabetes
on depression, because this association
may be bidirectional (2). To date, the ev-
idence on the status of depressive symp-
toms as a risk factor for type 2 diabetes is
mixed as both supportive and null ﬁnd-
ings have been reported (2,5). It is there-
fore important to assess depression both
before and after the diagnosis of diabetes
inasinglemethodologicalsetuptoensure
adequate estimation of the effect sizes in
both directions. To our knowledge, no
such study exists.
In this study, we used multiple re-
peated measurements of antidepressant
use, both before and after the diagnosis of
type 2 diabetes, to examine whether
awareness of diabetes diagnosis is associ-
ated with elevations in depression risk
and whether individuals who develop
type 2 diabetes are more likely to be de-
pressed already before the diagnosis than
their nondiabetic counterparts. For com-
parison, we examine antidepressant use
among individuals who developed can-
cer, a disease that is known to increase
risk of depression (6).
RESEARCH DESIGN AND
METHODS— Data were drawn from
theFinnishPublicSectorstudy(7),which
includes the entire public sector person-
nel of 10 towns (municipalities) and 21
hospitals in the areas where these towns
are located (see supplementary Figs. S1
and S2, available in an online appendix
at http://care.diabetesjournals.org/cgi/
content/full/dc09-2359/DC1). The eligi-
ble population comprised 151,347 em-
ployees with an employment contract
between 1995 and 2005 with a record
linkage to national health registers through
uniquepersonalidentiﬁcationcodes,which
areassignedtoallcitizensinFinland.Forall
the participants in the eligible population,
thelinkagetoregisterswas100%complete,
andtherewasnosampleattritionduringthe
follow-up.
We report data from two indepen-
dentcohorts:493participantswhodevel-
opedtype2diabetes(hereafterreferredto
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uals who developed cancer (the “cancer
study”). All participants in both studies
had complete data on prescribed antide-
pressant use and other register measures
overaﬁxedperiodof4yearsbeforeand4
years after the diagnosis of type 2 diabe-
tes/cancer, because we limited the study
to those participants with incident case
subjects who received the diagnosis of di-
abetes or cancer between 1 January 1999
and 31 December 2001 and were alive a
minimum of 4 years after the diagnosis.
This ensured an observation period of 4
years before and after the diagnosis with-
out any sample attrition.
We randomly selected control sub-
jects in a 5:1 ratio for each diabetes case
subject and each cancer case subject,
matching individually for age-group (25–
45, 46–52, and 53–64 years), sex, socio-
economic position (upper nonmanual,
lower nonmanual, or manual), type of
employment contract (permanent vs.
temporary), type of employer (hospital
vs. municipality), and geographic area
(seven areas based on the location of the
workplace), because these characteristics
could be related to differences in the like-
lihood of achieving diagnosis or treat-
ment. The diabetes study included 2,450
matched diabetes-free control subjects
and the cancer study included 3,730
matched cancer-free control subjects.
Assessment of antidepressant use
Depression was approximated from anti-
depressant use for each year of the obser-
vation period from 4 years before to 4
years after the diabetes and cancer diag-
noses using the nationwide Drug Pre-
scription Register. We used the same
period for the incident diabetes/cancer
case subjects and their disease-free con-
trol subjects to avoid confounding due to
secular trends in antidepressant use. In
Finland, prescriptions for antidepressant
medications are ﬁled by the National So-
cial Insurance Scheme at the Social Insur-
ance Institution, and the available data
contain information on the day of pur-
chase, dose, stated as the international
standard daily deﬁned dose, and medica-
tion classiﬁed according to the World
Health Organization Anatomical Thera-
peutic Chemical (ATC) classiﬁcation (8).
For each year of observation, we deﬁned
antidepressant use as the purchase of an-
tidepressants(ATCcodeN06A)ofatleast
30 daily deﬁned doses. In addition, we
conducted a sensitivity analysis, limiting
the analysis to selective-serotonin re-
uptake inhibitor (SSRI) (ATC code
N06AB) as the outcome because these
drugs have a lower risk of cardiotoxicity
than tricyclic antidepressants and there-
fore may be more likely to be selectively
prescribed in individuals with diabetes.
Case deﬁnition for incident type 2
diabetes and cancer
Since 1965, drug treatment for diabetes
has been free of charge in Finland. The
Central Drug Register, maintained by the
Social Insurance Institution, lists all such
individuals with physician-documented
evidenceofafastingplasmaglucose7.0
mmol/l or a nonfasting plasma glucose
11.1mmol/landsymptomsofdiabetes,
such as polyuria, polydipsia, and glucos-
uria. If the symptoms are not present,
then evidence of repeatedly measured el-
evated glucose levels is required. In this
study, participants were deﬁned as those
with incident case subjects of type 2 dia-
betes the ﬁrst time they were listed in the
Central Drug Register as eligible for dia-
betes treatment between 1 January 1999
and 31 December 2001.
Toexcludeindividualswithtype1di-
abetes, we additionally linked the data to
the Finnish Hospital Discharge Register
that lists all discharged hospital patients
with information on dates of admission
and discharge and to the Drug Prescrip-
tion Register (Social Insurance Institu-
tion) that includes all prescriptions for
insulinmedications,drugstolowerblood
glucose, and other drugs for diabetes in
Finland nationwide since 1994, accord-
ing to the World Health Organization
ATC classiﬁcation. We excluded individ-
uals who were recorded as having type 1
diabetes(ICD-10codeE10)intheCentral
Drug Register or the Hospital Discharge
Register. For these registers, type 1 diabe-
tes is always diagnosed by a diabetes spe-
cialist. For sensitivity analyses, we
additionally excluded from the case sub-
jectsthoseforwhominsulinoritsanalogs
(ATC code A10A, the Drug Prescription
Register) were prescribed and who had a
diagnosis of diabetes at age 35 years.
Individualswithtype1diabeteswerealso
not allowed to be selected as control sub-
jects. From the potential control group,
weexcludedallindividualswithprescrip-
tions for insulin or its analogs, blood
glucose–lowering drugs, or other drugs
for diabetes during any of the years of ob-
servation in the Central Drug Register,
Hospital Discharge Register, and Drug
Prescription Register.
Individuals with cancer were identi-
ﬁed via the nationwide Finnish Cancer
Register, which records all patients with
any type of cancer. In Finland, all physi-
cians, all hospitals, and other institutions
are legally bound to send notiﬁcations of
all malignant tumors, carcinoid tumors,
carcinoma in situ lesions, and tumors
with borderline malignancy to the Regis-
ter. In this study, an individual was de-
ﬁned as a cancer case subject if he or she
had the diagnosis of cancer for the ﬁrst
time between 1 January 1999 and 31 De-
cember 2001.
Other variables
Age, sex, socioeconomic position (upper
nonmanual, lower nonmanual, or man-
ual), type of employment contract (per-
manent vs. temporary), type of employer
(hospital vs. municipality) and geographic
area (seven areas based on the location of
the workplace) were obtained from em-
ployers’ registers. Age at diagnosis was
calculatedfromthedatesofdiagnosisand
birth, using register data. We assessed the
status of coronary heart disease at each
year of observation, because this condi-
tion is known to be associated with both
depression and diabetes. Information on
coronary heart disease was obtained from
the Finnish Hospital Discharge Register
and Central Drug Register (ICD-10 codes
I20–I25).
Statistical analysis
We analyzed the diabetes study and the
cancer study separately. The observation
period started at the date of diagnosis
(year 0) for those who developed type 2
diabetes or had cancer (i.e., case subjects)
and at a matched year for the control sub-
jects. Participants were then traced back-
ward and forward from year 0 to assess
antidepressantuseforaperiodcovering4
years before and 4 years after the diagno-
sis(i.e.,years4to4).Weappliedare-
peated-measures logistic regression
analysis using the generalized estimating
equations method to estimate trajectories
of antidepressant use before and after the
diagnosis (for details, see supplementary
data,availableinanonlineappendix).We
conducted all analyses using STATA sta-
tistical software (version 10.1 for Win-
dows). Statistical signiﬁcance was inferred
at a two-tailed P  0.05.
RESULTS— Table 1 shows the char-
acteristics of participants at baseline, i.e.,
4 years before the diagnosis in case sub-
jects. In the studies of type 2 diabetes and
cancer, there were no differences in base-
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casesubjectsanddisease-freeparticipants
(P  0.11), including job type and geo-
graphical area that are not shown in the
tables(P0.95inthediabetesstudyand
P  0.93 in the cancer study). Compari-
son of the two studies shows that partici-
pantsinthediabetesstudywere2.4(95%
CI 2.2–2.7) years older, more likely to be
male (odds ratio [OR] 2.80 [95% CI
2.64–2.97]) and with a manual occupa-
tion (2.25 [2.15–2.38]) compared with
participants from the cancer study. These
differences were expected, given that
male sex and low socioeconomic posi-
tion tend to be stronger risk factors for
type 2 diabetes than cancer in working
populations.
Antidepressant use before and after
diagnosis of diabetes
Crude ORs for antidepressant use among
incident diabetes case subjects versus
nondiabetic control subjects at each year
of observation were 2.19 (year 4), 1.95,
1.90, 2.33, 2.66 (year 0, diagnosis), 1.93,
1.73, 1.87, and 1.97 (year 4). The 95%
CIs for the lowest OR, 1.73, were 1.2–
2.38 and for the highest OR (year of diag-
nosis) were 1.94–3.65 (complete results
available upon request from the ﬁrst
author).
Figure 1 shows the ﬁnal model to de-
scribe the trajectory of antidepressant use
among incident diabetes case subjects
and nondiabetic control subjects (for
modelparameters,seesupplementaryTa-
ble S1, available in an online appendix).
There was an overall upward trend in the
use of antidepressants across the 9-year
observation period in diabetes case sub-
jects and control subjects (time P 
0.0001), reﬂecting the nationwide in-
crease in prescription of these drugs (15).
Across the entire observation period, the
OR of antidepressant use was 2.00 (95%
CI 1.57–2.55) times higher for the inci-
dent diabetes case subjects than for the
control subjects (P  0.0001). There
were no differences in the antidepressant
slopes between the groups before or after
the diagnosis (P  0.32), except for the
temporary increase in antidepressant use
during the year of diagnosis among the
incident diabetes case subjects (P 
0.01).
In four sensitivity analyses we re-
peated the main analysis ﬁrst, after exclu-
sionofallincidentcasesubjectswhowere
receiving insulin treatment and those
aged 35 years at the time of diagnosis;
second, after exclusion of subjects with
prevalent coronary heart disease; third,
with adjustment for socioeconomic posi-
tion, job contract, and geographical area
in the model; and fourth, with SSRIs as
the outcome. These sensitivity analyses
largely replicated the ﬁndings in the main
analysis (supplementary Tables S2 and
S3, available in an online appendix).
Antidepressant use before and after
diagnosis of cancer
Figure 2 presents the ﬁnal model to de-
scribe trajectories in antidepressant use
before and after the diagnosis of cancer
(for model parameters, see supplemen-
tary Table S1). The slope in antidepres-
sant use did not differ between case
subjects and control subjects before year
Figure 1—Probability (95% CI) of antidepressant use before and after diagnosis of type 2
diabetes.
Table 1—Baseline characteristics of study participants
Diabetes study* Cancer study*
Incident case
subjects
Control
subjects
P
value
Incident case
subjects
Control
subjects
P
value
Total N 2,943 4,478
n 493 2,450 748 3,730
Male sex 42.0 41.8 0.95 18.7 18.5 0.83
Age-group 0.11 0.39
26–44 years 18.9 23.8 31.2 34.3
45–54 years 48.1 45.7 42.4 41.8
45–64 years 30.6 28.7 24.1 21.9
65–70 years 2.4 1.8 2.1 2.0
Age (years) 50.9  7.4 50.0  8.1 47.9  9.6 47.7  8.9
Socioeconomic position 0.95 1.00
Upper nonmanual 19.1 19.2 33.2 33.2
Lower nonmanual 39.2 39.2 43.6 43.7
Manual 41.8 41.6 23.3 23.2
Prevalent coronary heart
disease 3.3 2.4 0.28 2.1 1.5 0.17
Data are means  SD or %. *There were no missing data in any of the variables.
Kivima ¨ki and Associates
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the year of diagnosis was slightly higher
among incident cancer case subjects than
among control subjects (P0.03). There
was a substantial increase in antidepres-
sant use in case subjects after the diagno-
sis (12.2% 1 year after the diagnosis
compared with 6.3% in the year before
the diagnosis; caseness  period P 
0.004). The OR of antidepressant use was
1.92 (95% CI 1.49–2.48) times higher in
incident cancer case subjects 1 year after
the diagnosis compared with that in con-
trol subjects. Antidepressant use declined
somewhat in the 2nd year after the diag-
nosisofcancer(casenesstimeperiod
P0.01)butremainedhigherinincident
cancer case subjects compared with can-
cer-free control subjects for the whole
4-year period after diagnosis.
CONCLUSIONS — Serial measure-
ments show that antidepressant use
among men and women who develop
type2diabeteswas2timesgreaterthan
that in nondiabetic individuals. Except
for a temporary change in risk at the year
of diagnosis, the relative difference in an-
tidepressant use between these groups
was similar during the 4 years before and
4 years after the diagnosis of diabetes. In
contrast, there was no difference in anti-
depressant use before diagnosis of cancer
between the incident case subjects and
cancer-freeparticipants,buttheuseofan-
tidepressantsincreasedsharplyafterdiag-
nosis and remained higher in case
subjects throughout the 4 years after
diagnosis.
Our ﬁndings provide support for the
hypothesis that awareness of the diagno-
sis of type 2 diabetes may temporarily in-
crease the risk of depressive symptoms.
However,becauseantidepressantusewas
similarly elevated both before and after
the diagnosis among diabetes case sub-
jects, it seems likely that awareness of the
diagnosis has no lasting effect on depres-
sion risk. These ﬁndings do not support
the concern that overlap of symptoms be-
tween type 2 diabetes and depression
(e.g.,fatigue)wouldmakeitlesslikelyfor
depression to be appropriately recog-
nized in diabetic patients (9).
It is possible that regular contact with
a physician after diagnosis of type 2 dia-
betes makes detection of unrecognized
depression more likely, explaining the
observed increase in the use of antide-
pressants. However, if this were to be the
case, prescription rates would have re-
mained high after diagnosis over the
4-year observation period. This was not
the case. Therefore, we believe that the
temporaryelevationinantidepressantuse
represents a true temporary increase in
depression risk as a result of the diagno-
sis.Theresultsobtainedforcancer,show-
ing elevated depression rates over the
entire postdiagnosis period, demonstrate
that our methodology was sensitive for
detecting long-term changes in depres-
siontrajectorieswhenthesewerepresent.
There are several possible explana-
tions for more prevalent use of antide-
pressants already before the diagnosis of
diabetes: First, it is possible that depres-
sion, as indicated by antidepressant use,
increases the risk of type 2 diabetes. Most
of the existing evidence provides support
for such an association (2,5). Indeed, de-
pression is associated with several behav-
ioral and metabolic factors that can
increase the risk of diabetes and insulin
resistance, including obesity-promoting
healthbehaviors,suchasphysicalinactiv-
ity and hypercaloric diets (10,11) and ac-
tivation of the neuroendocrine (12) and
inﬂammatory responses (13).
Second, it is also conceivable that the
bidirectional association between depres-
sion and diabetes in adulthood is a con-
sequence of early factors, such as low
birth weight and childhood adversity,
which predispose individuals to both de-
pression (14) and obesity/type 2 diabetes
(15,16). However, further research is
neededtotestthishypothesisempirically.
Third, there is some, although not
completely consistent, evidence that spe-
ciﬁc antidepressant drugs may increase
theriskofdiabetes(17–19).IntheDiabe-
tesPreventionProgram(DPP)forindivid-
uals at high risk for developing type 2
diabetes,astrongassociationbetweenan-
tidepressant use and subsequent diabetes
onset was not accounted for by measured
confounders or mediators (17). It is also
known that tricyclic antidepressants and
noradrenergic and speciﬁc serotonin an-
tidepressantsmayinduceweightgainand
promote hyperglycemia (20,21). In con-
trast, SSRIs and related agents may, at
least in the short-term, be related to re-
duced weight gain and improved insulin
sensitivity (22). However, in our investi-
gation those treated with SSRIs had an
increased risk of incident diabetes and in
the DPP study the association between
antidepressant use and diabetes risk was
notaccountedforbyweightchanges(17).
Finally, the notion that undiagnosed
diabetes is more likely to be picked up in
individuals who see their physician for
depression could explain the more prev-
alent use of antidepressants before the di-
agnosis of diabetes. However, this
interpretation is not consistent with re-
centstudiesshowingbothtreatedandun-
treated depression to be related to an
elevated risk of diabetes (19).
Figure 2—Probability (95% CI) of antidepressant use before and after diagnosis of cancer.
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Nine repeated measurements of antide-
pressant drug use, encompassing the pe-
riod both before and after diagnosis,
enabled a better characterization of the
association between diabetes diagnosis
and antidepressant use than was possible
in previous studies with fewer measure-
ment points. Comprehensive records
fromnationalregistersmadeitpossibleto
avoid biases related to sample attrition.
Becauseweselectedmatchedcontrolsub-
jects for socioeconomic position and
other key confounding factors, major
confoundingduetosocialstratiﬁcationof
type2diabetesortreatmentofthisdisease
is unlikely. Our study design is more ef-
fective in reducing confounding than a
simple multivariate adjustment in the to-
tal cohort, the most widely used method
in this ﬁeld of research. However, no ob-
servational study can exclude the possi-
bility of residual confounding.
Weincludedinthestudyparticipants
alive 4 years after diagnosis. This ap-
proachimpliesthatpatientswiththemost
aggressivecancersleadingtodeathwithin
the ﬁrst 4 years were excluded. Because
thesepatientsareparticularlylikelytoex-
perience depression, our ﬁndings may
provide an underestimate of postcancer
antidepressant use. In contrast, for dia-
betic patients 4 years of follow-up proba-
bly did not capture all of the potentially
detrimental psychological impact that
may become most apparent when pa-
tients have reached an advanced state of
diabetes and experience the burden of
dealing with its complications. Our ﬁnd-
ings on postdiabetes antidepressant use
may therefore provide a conservative
estimate.
Misclassiﬁcation between type 1 and
type 2 diabetes is a source of potential
error in epidemiological studies on type 2
diabetes.Oursensitivityanalyses,exclud-
ing all individuals with diabetes who are
receiving insulin treatment and who are
aged 35 years, suggest that our ﬁndings
are not due to falsely coded type 1 diabe-
tes. In this study, 25% of the incident di-
abetescasesubjectswerereceivinginsulin
therapy 4 years after the diagnosis. It is
likely that most of these case subjects
were true type 2 diabetic patients, as the
projected need for insulin therapy for pa-
tientswithtype2diabetesis20%inthis
time window.
TheFinnishnationwideregistriesval-
idly identiﬁed individuals pharmacologi-
cally treated for type 2 diabetes and
depression but did not capture undiag-
nosed disease or conditions treated with-
out medication. Furthermore, in addition
to depression, antidepressants are used in
the treatment of other disorders, such as
chronic pain and sleeping disorders, and
they are sometimes prescribed for smok-
ing cessation. When the present data are
interpreted, it is important to recognize
that antidepressant treatment is not ex-
actly the same as a diagnosis of depression,
although patients with such disorders rep-
resent a vast majority of those taking
antidepressants.
We could not address some poten-
tiallyimportantissues,suchastheprecise
timing of diabetes onset (rather than
when it was recognized), the severity of
depression,andthestatusofotherclinical
conditions, because all of these would re-
quire a clinical examination. With re-
peated clinical examinations, however,
the present study design with nine serial
assessments around the diagnosis would
be very expensive to undertake (the cur-
rent study is based on 151,618 individu-
als followed up for 11 years). Therefore,
future researchers should seek solutions
to overcome these limitations.
Implications
Depression is known to be associated
with poor glycemic control and negative
clinical outcomes (23,24). We found that
individualswitharecentdiagnosisoftype
2 diabetes had an excess use of antide-
pressants similar in size to that among
4-year cancer survivors immediately after
diagnosis. Our ﬁndings support the rec-
ommendation of the American Diabetes
Association to screen diabetic patients for
depression (25).
Our ﬁnding that elevated antidepres-
sant use exists already before the diagno-
sis of diabetes warrants further research.
Because these agents are routinely offered
to patients with moderate and severe de-
pression, it would be important to deter-
mine whether antidepressants have side
effects that increase diabetes risk and, if
this were the case, make appropriate
modiﬁcationstothetreatmentofpatients.
It is also possible that depression rather
than antidepressant use is a risk factor for
diabetes or that the two share common
risk factors, indicating that research is
needed to assess the potential beneﬁts of
diabetes prevention interventions tar-
geted especially to patients treated for
depression.
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